arrow
L

Lluís Ramió-Torrentà

girona biomedical research institute (idibgi-cerca)
H指数:37
被引数:6,046

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From adaptive to maladaptive hippocampal resting-state functional connectivity over the course of multiple sclerosis to understand memory impairment

从适应性到非适应性的海马体静息态功能连接,在多发性硬化症病程中理解记忆障碍

2025-11-040
OAAI
Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis

鉴定与炎症和神经退行性变相关的多发性硬化细胞因子

2025-08-070
OA
An expert patient program for people living with multiple sclerosis improves knowledge and empowerment: a pre-test, post-test multicenter implementation study

一项针对多发性硬化患者的专家患者计划提高了知识和赋权:一项预测试、后测试多中心实施研究

2025-04-290
OA
Economic burden of secondary progressive multiple sclerosis: DISCOVER study

继发性进展型多发性硬化症的经济负担:DISCOVER研究

2025-04-100
OA
Archaea methanogens are associated with cognitive performance through the shaping of gut microbiota, butyrate and histidine metabolism

古菌产甲烷菌通过塑造肠道微生物群、丁酸盐和组氨酸代谢与认知功能相关。

2025-02-052
OAAI
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
2025-01-010
PRE
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis (vol 15, 1480676, 2024)
2024-12-190
OAAI
Microviridae bacteriophages influence behavioural hallmarks of food addiction via tryptophan and tyrosine signalling pathways
2024-11-251
PRE
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis

ocrelizumab治疗复发缓解型多发性硬化反应的生物标志物

2024-11-120
OAAI
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis
BRAIN
IF11.7
2024-08-052
PRE
A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression

fingolimod的一项为期两年的实时研究: 疗效的早期预测指标以及EBNA-1 IgG滴度与多发性硬化进展之间的关联

2024-06-070
OAAI
Gut microbiota links to serum ferritin and cognition
2023-12-076
OAAI
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

多发性硬化症患者在疾病改善疗法下的SARS-CoV-2血清阳性率: 一项多中心研究

2023-11-230
OAAI
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

血清生物标志物水平预测原发性进行性多发性硬化患者的残疾进展

2023-11-086
PRE
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
2023-10-200
OAAI